TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15117326
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b plus ribavirin (RBV) 1000-1200 mg/day for 48 weeks (Study 1)
Study: 15117326
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b plus ribavirin (RBV) 1000-1200 mg/day for 4 weeks followed by three times weekly dosing for 44 weeks (Study 2)
Study: 15117326
Drug: RBV dose
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV dose reduction
Study: 15117326
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b daily use
Study: 11208843
Drug: 4-week chemotherapy
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week chemotherapy regimen (vincristine and actinomycin D)
Study: 11208843
Drug: 8-week chemotherapy
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week chemotherapy regimen (vincristine and actinomycin D)
Study: 11208843
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (NFT) for stage I favorable histology (n = 5)
Study: 7883388
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg t.i.d. intravenously for 3-21 days (mean 5.4 days)
Study: 7883388
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg/500 mg t.i.d. intravenously for 3-17 days (mean 5.1 days)
Study: 3284283
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine chewing gum (n = 62)
Study: 3284283
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine chewing gum (n = 54)
Study: 3284283
Drug: Group counselling
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group counselling with nicotine gum (2 mg or 4 mg)
Study: 21115872
Drug: Topotecan Weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan Weekly (Tw) 4 mg/m²/week administered on days 1, 8, and 15
Study: 21115872
Drug: Conventional 5-Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 5-Day Schedule (Tc) 1.25 mg/m²/day on days 1 to 5
Study: 21115872
Drug: Topotecan Weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan Weekly (Tw)
Study: 15936996
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin daily
Study: 16854404
Drug: Recutin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recutin (100 mg)
Study: 16854404
Drug: Polybutin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polybutin (100 mg)
Study: 8665993
Drug: BAY t
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY t 7207 (20 mg)
Study: 2225152
Drug: Indomethacin 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.5% eye drops administered three times a day from the day prior to operation to the 10th day after operation
Study: 2225152
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times a day from the day prior to operation to the 10th day after operation
Study: 25546164
Drug: Voglibose/metformin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose/metformin fixed-dose combination (FDC)
Study: 25546164
Drug: Coadministered individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coadministered individual voglibose and metformin tablets
Study: 23690755
Drug: Facilitation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitation of local stakeholder groups (laywomen facilitated monthly meetings for 3 years)
Study: 17338610
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 30 mg/kg intravenously as a bolus followed by a continuous infusion of 10 mg/kg/hr starting 15 minutes before induction of sedation.
Study: 11370752
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of weekly fluoride rinsing (test group)
Study: 11370752
Drug: Weekly rinsing
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly rinsing with 0.2% sodium fluoride solution (control group)
Study: 9112137
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg x kg‐1 ketorolac
Study: 9112137
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg x kg‐1 ketorolac
Study: 1439622
Drug: Arthrotec (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrotec (50 mg diclofenac + 200 micrograms misoprostol)
Study: 4091997
Drug: Ethanol consumption
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol consumption (80 g per day)
Study: 23344135
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (statutory drug education) for LR youth
Study: 21155908
Drug: Cross-intolerance (CI)
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-intolerance (CI) to NSAIDs, primarily involving propionic acid derivatives like ibuprofen.
Study: 16042878
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg entecavir
Study: 18554238
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg entecavir
Study: 11550573
Drug: Standard inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard inactivated whole‐virion influenza vaccine (0.5 ml subcutaneously in a single injection)
Study: 11550573
Drug: Standard inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard inactivated whole‐virion influenza vaccine (intranasally in two administrations)
Study: 11550573
Drug: Standard inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard inactivated whole‐virion influenza vaccine (intranasally)
Study: 11550573
Drug: Preparation 'Amber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation 'Amber elixir plus'
Study: 8112372
Drug: Intravenous 14C‐fosinoprilat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 14C‐fosinoprilat (7.5 mg)
Study: 8112372
Drug: Oral 14C‐fosinopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 14C‐fosinopril sodium (10 mg)
Study: 8112372
Drug: Oral fosinopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fosinopril sodium (10 mg)
Study: 3086388
Drug: Rifampin therapy
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin therapy (5 days) in combination with penicillin or erythromycin (10-14 days)
Study: 31926037
Drug: Blood donors
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood donors with lead concentrations over the limit for transfusions in premature infants (0.09 μmol/L)
Study: 31926037
Drug: Blood donors
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood donors with mercury concentrations over the suggested limit (23.7 nmol/L)
Study: 31926037
Drug: Blood donors
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood donors with cadmium concentrations over the limit (16 nmol/L)
Study: 31926037
Drug: Blood donors
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood donors with perfluorooctanoate (PFOA) concentrations over the suggested limit (0.91 ng/mL)
Study: 31926037
Drug: Blood donors
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood donors with perfluorooctane sulfonate (PFOS) concentrations over the suggested limit (0.91 ng/mL)
Study: 23609425
Drug: Sputum induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sputum induction by inhalation of hypertonic saline
Study: 19451828
Drug: Standard-of-care antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care antipsychotics
Study: 16433729
Drug: Transdermal alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal alcohol monitoring device (anklet)
Study: 16433729
Drug: Self-reported drinking
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported drinking log and transdermal alcohol monitoring device
Study: 16433729
Drug: Transdermal alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal alcohol monitoring device
Study: 14654535
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (40 mg/instillation)
Study: 10838647
Drug: Meningococcal C
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal C conjugate vaccine (0.5 mL doses, groups 1 and 2; n=60 each)
Study: 10838647
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B control vaccine (group 3; n=62)
Study: 10452046
Drug: Local delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local delivery of drugs (prednisolone and procaine) during tissue expansion
Study: 10452046
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no local drug delivery)
Study: 1589555
Drug: Trihexyphenidyl (THP)
DrugBank: Trihexyphenidyl (DB00376)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trihexyphenidyl (THP) 2 mg, 4 mg
Study: 1589555
Drug: Biperiden (BPD)
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biperiden (BPD) 1 mg, 2 mg, 5 mg
Study: 1589555
Drug: Mazaticol (MZC)
Normalized name: mazaticol
DrugBank: Mazaticol (DB13448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazaticol (MZC) 4 mg, 8 mg
Study: 1589555
Drug: L-dopa (LDP)
Normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: L-dopa (LDP) 100 mg
Study: 1589555
Drug: Bromocriptine (BMC)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (BMC) 1.25 mg, 2.5 mg
Study: 1589555
Drug: Amantadine (AMD)
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine (AMD) 100 mg
Study: 1589555
Drug: Amitriptyline (ATP)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline (ATP) 25 mg
Study: 1589555
Drug: Haloperidol (HPD)
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol (HPD) 3 mg
Study: 1589555
Drug: Diazepam (DZP)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZP) 3 mg
Study: 3896595
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg, b.d.)
Study: 29746229
Drug: Intraperitoneal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal and intravenous paclitaxel plus S-1 (IP); intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 plus S-1 80 mg/m2 per day on days 1 to 14 for a 3-week cycle
Study: 29746229
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus cisplatin (SP); S-1 80 mg/m2 per day on days 1 to 21 plus cisplatin 60 mg/m2 on day 8 for a 5-week cycle
Study: 24665241
Drug: I.V ramosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V ramosetron 0.3 mg
Study: 24665241
Drug: I.V Ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V Ondansetron 4 mg
Study: 23460233
Drug: Deferiprone monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone monotherapy, average dose 79.1±4.3 mg/kg/day
Study: 23460233
Drug: Deferiprone monotherapy
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone monotherapy
Study: 7653685
Drug: Counseling plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling plus supplemental drug counseling
Study: 791192
Drug: BA‐34647 (experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA‐34647 (experimental antispasticity drug)
Study: 31847158
Drug: Soft tissue
Normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft tissue therapy (additional therapy program alongside standard physical therapy)
Study: 27368000
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine (5 mg/kg)
Study: 15587094
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.7 mg/kg)
Study: 25144127
Drug: Intracameral MFLX
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral MFLX (150 μg/mL) in left eye, balanced salt solution in right eye (Group A)
Study: 25144127
Drug: Intracameral MFLX
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral MFLX (500 μg/mL in right eye, 150 μg/mL in left eye) (Group B)
Study: 25144127
Drug: Intracameral MFLX
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral MFLX (150-500 μg/mL)
Study: 22124104
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus surgery (gemcitabine 1,250 mg/m² days 1 and 8 every 3 weeks plus cisplatin 75 mg/m² day 1 every 3 weeks followed by surgery)
Study: 17488461
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia (TA)
Study: 31841026
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of dobutamine and terlipressin
Study: 31152372
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL boluses of bupivacaine 0.125% with fentanyl 2 µg·mL-1
Study: 24125150
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol 80 μg
Study: 24125150
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol 160 μg
Study: 19683881
Drug: Artelon implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artelon implant
Study: 19683881
Drug: APL tendon
Normalized name: Bos taurus tendon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL tendon suspension interposition arthroplasty
Study: 18184530
Drug: Basal Supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal Supported Oral Treatment (BOT) - insulin glargine combined with glimepiride and metformin
Study: 18184530
Drug: Conventional Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Therapy (CT) - premixed insulin
Study: 1785707
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (5 micrograms.kg‐1 during the first hour, and 0.3 microgram.kg‐1.h‐1 thereafter)
Study: 7265042
Drug: Standard film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard film taken during arterial time after contrast medium injection
Study: 28422864
Drug: Ketamine (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (100, 200, 1000 ng/mL)
Study: 28422864
Drug: Morphine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (200 ng/mL)
Study: 16759047
Drug: Treatment interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment interruption
Study: 24797262
Drug: Treatment interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment interruption in patients with low on-treatment levels of serum IFN‐γ
Study: 12190751
Drug: Oral flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral flumazenil
Study: 8813983
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with additional biofeedback training (CT+BF)
Study: 2861567
Drug: OKT3 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 monoclonal antibody treatment for acute rejection, daily for a mean of 14 days, with concomitant lowering of other immunosuppressive drugs.
Study: 2861567
Drug: Conventional high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional high-dose steroids treatment for acute rejection.
Study: 2861567
Drug: OKT3 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OKT3 treatment group.
Study: 2861567
Drug: Conventional high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional high-dose steroids treatment group.
Study: 22842057
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of tranexamic acid (5 g in 100 ml saline solution)
Study: 22842057
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml saline solution)
Study: 19948872
Drug: GFR <60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR <60 ml/min/1.73 m(2)
Study: 19948872
Drug: GFR <60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR <60 ml/min/1.73 m(2) in women without pre-existing CVD
Study: 17627004
Drug: Combination low-fat/high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination low-fat/high fruit-vegetable diet
Study: 8645892
Drug: Moderate hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hydration plus ANP infusion (ANP group)
Study: 10411764
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam premedication
Study: 7871107
Drug: Established biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established biological risk factors (serum low-density lipoprotein cholesterol concentration, smoking, old age)
Study: 3175455
Drug: Decreased spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased spray cone angle from 60 degrees to 35 degrees
Study: 30094707
Drug: Adjuvant radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiochemotherapy and chemotherapy
Study: 27038440
Drug: betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: betamethasone valerate cream
Study: 27038440
Drug: roflumilast 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: roflumilast 0.5% cream
Study: 27038440
Drug: TAK‐084 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK‐084 0.5% cream
Study: 27038440
Drug: TAK‐084 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK‐084 5% cream
Study: 27038440
Drug: calcipotriol 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcipotriol 0.005% cream
Study: 23601333
Drug: Antibiotics (norfloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (norfloxacin 400 mg BD)
Study: 23601333
Drug: Antibiotics (norfloxacin)
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics (norfloxacin)
Study: 20152700
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dyssynchrony with epsilon-pl < -7.8%
Study: 2019161
Drug: Metaproterenol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (5 percent solution, 0.3 ml) plus atropine sulfate (2.5 mg)
Study: 2019161
Drug: Metaproterenol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (5 percent solution, 0.3 ml) alone
Study: 28758951
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (Fe condition) - 12 mg of iron twice daily (24 mg/day)
Study: 18007083
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (6 mL/kg)
Study: 23880084
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume ventilation (12 mL/kg)
Study: 26725184
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg orally daily)
Study: 11468032
Drug: Etifoxine 50
Normalized name: etifoxine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etifoxine 50 mg
Study: 11468032
Drug: Etifoxine 100
Normalized name: etifoxine
DrugBank: Etifoxine (DB08986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etifoxine 100 mg
Study: 9763356
Drug: Vitamins (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins (specific type and dosage not mentioned)
Study: 28376756
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided needling and lavage (barbotage) with subacromial steroid injection
Study: 28376756
Drug: Sham barbotage
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham barbotage with subacromial steroid injection
Study: 28376756
Drug: Sham barbotage
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham barbotage without subacromial steroid injection (placebo group)
Study: 21450115
Drug: dairy-Se (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: dairy-Se (150 μg/d)
Study: 21450115
Drug: yeast-Se (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: yeast-Se (150 μg/d)
Study: 15483410
Drug: Aselizumab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aselizumab 0.5 mg/kg
Study: 15483410
Drug: Aselizumab 1
Normalized name: atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aselizumab 1 mg/kg
Study: 15483410
Drug: Aselizumab 2
Normalized name: atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aselizumab 2 mg/kg